The COVID Advisor

Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. Updates:  Ivermectin, Hydroxychloroquine Use Soared During COVID-19 Pandemic: 2025 Study 53,000+ Patient Study Finds Low-Dose Hydroxychloroquine Associated with Reduced COVID-19 Mortality in China (Frontiers of Medicine 2025) Note: highlighting his objectivity, while Pi...

A sudden rise in younger people with early onset cancers which are more aggressive with more (and unusual) genetic change has been increasingly noted - colorectal, breast and GI tract cancers seem to lead the way.   Dr. Harvey Risch first reported in September 2023 that Clinicians at Yale Medical School were seeing some new cancer situations in adults as young as 25, with no family history of developing colorectal cancer, suddenly developing highly aggressive forms of the disease. So aggressive that between diagnosis and first treatment, the cancers have grown dramatically (1). This phenomenon has rapidly accelerated since the Pandemic. These ‘turbo cancers’ do not conform to the normal behaviour of cancers, not only are they more aggressive, but there seem to be more genetic issues in these cancers. Risch is Professor Emeritus of Epidemiology in the Department of Epidemiology and Public Health at the Yale School of Public Health and Yale School of Medicine.   In 2022 ther...